Sentences with word «atomoxetine»

At present the only drugs licensed for use to improve academic performance are stimulants such as atomoxetine, for ADHD.

Just as Eli Lilly unfortunately found in atomoxetine, it is very difficult to switch from an unsuccessful argument for actual utility to sound prediction — because one is left with only the disclosure of the patent (and not the extensive tests relied on for actual secret utility).

Lilly's challenge is based on its patent case regarding the ADHD drug atomoxetine (2010 FC 915, 2011 FCA 220).

If a child doesn't respond well to stimulants, some doctors prescribe the non-stimulant atomoxetine (brand name: Strattera).

These medicines include atomoxetine (Strattera), clonidine (Kapvey), and guanfacine (Intuniv).

Other substances with similar modes of action, such as the norepinephrine reuptake inhibitor atomoxetine, work equally well.

A Systematic Review of Combination Therapy with Stimulants and Atomoxetine for Attention - Deficit / Hyperactivity Disorder, including Patient Characteristics, Treatment Strategies, Effectiveness, and Tolerability.

How would you treat a dog who ingested atomoxetine?

The benefit seen was comparable to what might be encountered for nonstimulant ADHD drugs such as atomoxetine (Strattera).

In particular, Eli Lilly claimed that the development of the «promise doctrine» in Canadian patent law led to the invalidation of patents protecting its drugs atomoxetine (Strattera ®) and olanzapine (Zyprexa ®) by Canadian courts, and that this doctrine was radically new, arbitrary, and discriminatory against pharmaceutical companies.

However, only two drugs, long - acting methylphenidate and the non-stimulant atomoxetine, are currently approved for the treatment of ADHD in Japan [13].

In the early 1990s, Eli Lilly applied for patent protection in Canada for two chemical compounds, olanzapine and atomoxetine.

Although the genetic links between norepinephrine and its receptors and transporters are not as clearly understood as those for dopamine, medications such as atomoxetine that inhibit norepinephrine reuptake by neurons do improve symptoms.

Medications used by patients in the study were: methylphenidate (Ritalin), dexmethylphenidate (Focalin), dextroamphetamine (Dexedrine), atomoxetine (Strattera) and lisdexamfetamine (Vyvanse).

A significantly smaller number used nonstimulant ADHD medication such as Strattera, or atomoxetine.

Paterson, N. E.; Ricciardi, J.; Wetzler, C.; Hanania, T. Sub-optimal performance in the 5 - choice serial reaction time task in rats was sensitive to methylphenidate, atomoxetine and d - amphetamine, but unaffected by the COMT inhibitor tolcapone.

Several of the compounds tested in the lab have been FDA - approved including aripiprazole (Abilify ®), brexpiprazole (Rexulti ®), iloperidone (Fanapt ®), asenapine (Saphris ®), vilazodone (Viibryd ®), atomoxetine (Strattera ®), and cariprazine (Vraylar ®).

There is an alternative, however: Atomoxetine, known by its brand name, Strattera, is the only nonstimulant ADHD drug sold in the United States — and the first ADHD drug to be approved specifically for adults, in 2002.

In 2002, the FDA approved the first nonstimulant drug for ADHD, atomoxetine (known by its brand name, Strattera).

Short - term trials involving adults with ADHD have shown significant improvements in symptoms with stimulants and atomoxetine; however, data on long - term Turn Your Excuses Into Action: The «Do What You Can» Guide from the Blind, Teenage Leader of the French Resistance

The olanzapine patent is a selection; the atomoxetine patent was directed at improved side effects after long term dosing.

theft) of their atomoxetine patent because it was invalidated in Canada based on a violation of international law.

Osmotically released methylphenidate is more effective than atomoxetine in children and adolescents with ADHD

atomoxetine (Strattera, marketed as a «non-stimulant,» although its mechanism of action and potential side effects are essentially equivalent to the «psychostimulant» medications)

Medications most likely to be helpful include the stimulants (various methylphenidate and amphetamine preparations) and the non-stimulant, atomoxetine.

With regard to nonstimulants such as atomoxetine, there are literally no controlled outcome data for children with ADHD who are younger than 5 years of age.

Both stimulants and atomoxetine are recommended as options for the management of ADHD and / or ODD in children and adolescents.